Market Overview

Onconova Presents Positive Data from Clinical Trials of Rigosertib in MDS at ASH

Share:

Onconova Therapeutics (Nasdaq: ONTX) today announced two presentations relating to clinical trials of its most advanced product candidate, rigosertib, at the 55th American Society of Hematology (ASH) Annual Meeting in New Orleans, Louisiana, December 7-10, 2013. The presentations included data on efficacy, tolerability, and dosing regimen from the Phase 2 ONTARGET study of oral rigosertib in transfusion-dependent, lower risk MDS patients and response, overall survival, and longer-term follow-up data from a Phase 1/2 trial of intravenous (IV) rigosertib in higher risk post-hypomethylating agent-treated MDS and acute myeloid leukemia (AML) patients.#ASH13

See full press release

Posted-In: News Guidance Management Global

 

Related Articles (ONTX)

View Comments and Join the Discussion!